NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Dynavax Technologies Corporation (NASDAQ:DVAX) resulting from allegations that Dynavax may have issued materially misleading business information to the investing public.
On September 2, 2016, the U.S. Food and Drug Administration (“FDA”) announced that it had cancelled Dynavax’s November 16, 2016 meeting with the Vaccines and Related Biological Products Advisory Committee “to allow time for the FDA to review and resolve several outstanding issues” with Dynavax’s Biologics License Application for HEPLISAV-B™. The FDA further stated that it would schedule an Advisory Committee meeting in the future if necessary. On this news, shares of Dynavax dropped $5.03 or 32% from its previous closing price to close at $10.91 on September 2, 2016.
Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Dynavax investors. If you purchased shares of Dynavax on or before September 2, 2016, please visit the firm’s website at http://www.rosenlegal.com/cases-950.html for more information. You may also contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at firstname.lastname@example.org or email@example.com.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.